Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Ana Drozdowskyj, Bartomeu Massutí et al.|The Lancet Oncology|2012Cited by 5.5k
Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck CancerRicardo Hitt, H. Cortés-Funes, Antonio López–Pousa et al.|Journal of Clinical Oncology|2005Cited by 454